Last reviewed · How we verify
NCT03545425
Fox BioNet Project: LRRK2-002
trial testing Biofluid samplings in Parkinson Disease in 114 participants. Completed in 30 April 2020.
30 April 2020
Quick facts
| Lead sponsor | Michael J. Fox Foundation for Parkinson's Research |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 114 |
| Start date | 16 May 2018 |
| Primary completion | 30 April 2020 |
| Estimated completion | 30 April 2020 |
| Sites | 5 locations across United States |
Drugs / interventions tested
- Biofluid samplings
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
Sponsor
Michael J. Fox Foundation for Parkinson's Research
Who can join
30 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall objective of this study is to determine whether LRRK2 kinase activity and/or mitochondrial DNA (mtDNA) damage could serve as potential biomarkers in PD.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Participant-reported personal utility of genetic testing for Parkinson's disease and interest in clinical trial participation.
Oas H, Cook L, Schwantes-An TH, Walsh LE, et al · · 2024 · cited 3× · PMID 39455611 · DOI 10.1038/s41531-024-00805-z
Verify or expand the search:
- PubMed search for NCT03545425
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other Michael J. Fox Foundation for Parkinson's Research trials
Trials by the same sponsor.
- NCT04906590 — PPMI Tau PET Imaging · Phase 2 · completed
- NCT04603326 — FoxBioNet: ECV (Extracellular Vesicle) 004 · completed
- NCT06719583 — Black and African Americans Connections to Parkinson's Disease (BLAAC PD) · recruiting
- NCT03775447 — Fox BioNet Project: ECV-003 · completed
- NCT03170063 — FoxBioNet Pilot Project: SAVE (Synuclein Assay Validation Effort) · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03545425 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Michael J. Fox Foundation for Parkinson's Research
- Last refreshed: 8 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03545425.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing